{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-25-000230","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.427717+00:00","generated_at":"2026-05-17T01:01:50.146792+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vertex Q3 rev $3.08B (+11% YoY), FY guidance refined; povetacicept IgAN BLA on track","bullets":["Q3 total revenue $3.08B (+11% vs Q3 2024); GAAP net income $1.1B, non-GAAP $1.2B.","FY2025 revenue guidance raised to $11.9-12.0B; non-GAAP OpEx guidance $5.0-5.1B; tax rate lowered to 17-18%.","Povetacicept Phase 3 IgAN enrollment complete; first BLA module submission to FDA by end of 2025.","JOURNAVX: >300K prescriptions since March; CASGEVY: 165 cell collections, 39 infusions globally.","Zimislecel T1D trial enrollment complete; dosing temporarily postponed pending manufacturing analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-25-000230","json":"https://secwatch.observer/filing/0000875320-25-000230.json","markdown":"https://secwatch.observer/filing/0000875320-25-000230.md","text":"https://secwatch.observer/filing/0000875320-25-000230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/0000875320-25-000230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/vrtx-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:01:50.146792+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}